Twist Bioscience has completed a private placement of shares to raise $50m.

The company plans to use part of the proceeds towards investment in emerging market opportunities of digital data storage in DNA and drug discovery.

Based in the US, Twist Bioscience is a developer of a proprietary semiconductor-based synthetic DNA manufacturing.

Kangmei Pharmaceutical plans to issue medium-term notes in a public offering to raise CNY1bn ($159.21m).

Due March 2021, the medium-term notes carry a coupon rate of 6.1%.

Based in China, Kangmei is a pharmaceutical products manufacturer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

China Construction Bank Corporation and China Minsheng Bank are acting as underwriters for the transaction.

US-based pharmaceutical company ANI Pharmaceuticals has purchased the generic ANDA product portfolio from Australian pharmaceutical products provider IDT Australia for $2.73m.

“Kangmei Pharmaceutical plans to issue medium-term notes in a public offering to raise CNY1bn ($159.21m).”

ANI Pharmaceuticals acquired 23 previously marketed generic drug products in addition to active pharmaceutical ingredient (API) for $0.13m, as part of the acquisition.

IDT Australia will receive a share of the profits from the sale of Prazosin for a period of 60 months, upon its launch. It will also retain the right to produce and supply Doxazosin Mesylate and Calcium Leucovorin products, which are manufactured at its Boronia facilities.

ANI Pharmaceuticals will be responsible for the commercialisation and pharmacovigilance and regulatory costs of the divested ANDA product portfolio.

The acquisition will enable ANI Pharmaceuticals to build a pipeline of approved generic drug products.

Daiichi Sankyo and DarwinHealth have signed a research agreement, under which the latter will provide proprietary novel cancer target database to the former.

Darwin Health will receive an upfront payment and development and commercialisation milestone-based payments, as part of the agreement.

Based in Japan, Daiichi Sankyo is a pharmaceutical company, while DarwinHealth is a US-based precision therapeutics company focused on cancer medicine.

The agreement will enable both companies to identify novel, high-value cancer targets.